A Phase I/IIa Clinical Trial in Duchenne Muscular Dystrophy Using Systemically Delivered Morpholino Antisense Oligomer to Skip Exon 53 (SKIP-NMD)
HUMAN GENE THERAPY CLINICAL DEVELOPMENT(2015)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要
HUMAN GENE THERAPY CLINICAL DEVELOPMENT(2015)